Sarepta Therapeutics (SRPT.US) is trading under massive pressure today. Stock is down around 40% on the day, following disappointing results of drug trial. Early evidence suggested that Elevidys drug developed by Sarepta is effective in treatment of patients with Duchenne muscular dystrophy, leading the US Food and Drug Administration to approve its use for a limited number of patients.
However, final trial results that were just published turned out to be disappointing and were not statistically significant to rule the drug effective. As such, Sarepta failed to reach its primary goal, which was broader approval for Elevidys, and missed a chance to boost its sales.
Start investing today or test a free demo
Open account Try demo Download mobile app Download mobile appShares of Sarepta launched today's trading with a big bearish price gap. While part of the drop has been recovered during the cash session, stock is still around 40% lower on the day. A key, multi-year support zone in the $65 per share area is being tested at press time.
Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.